抗her-resisting her.docxVIP

After administrated the antibodies which were injected twice a week for consecutive 3 weeks via caudal vein, the nude mice were killed. The tumor inhibition ratio were measured, and the expression of VEGF and MVD values in these groups were detected by immunohistochemistry.3)In vitro, the anti-HER-2 engineering antibody ChA21（5 mg.L-1）combined withHerceptin（5 mg.L-1）treated with ovarian cancer SKOV3 cells. MTS assay was used for the analysis of cell growth, ELISA assay was employed to observe secreted VEGF in SKOV3 supernate fluid. The change of invasion ability of SKOV3 was detected by Transwell assay, the expression of VEGF、Akt/pAkt were assayed by western blotting. The alteration of HUVECs proliferation and migration were also been detected by MTS and Transwell assay, respectively.ResultsThe HER-2 overexpression rates, the positive rates of VEGF and MVD values in borderline tumor and carcinoma were significantly higher than those in serous cystadenoma (P0.01); The expresson of HER-2、VEGF and MVD were significantly positive correlation in serous cystadenocarcinoma (P0.01); The expresson of HER-2、 VEGF and MVD were closely correlated with tumor size and peritoneal cavity metastasis, but were little correlated with patient’s age and TNM stages(P0.05).The growth of SKOV3 xenografts in nude mice was significantly inhibited by ChA21 plus Herceptin treatment group than control group, ChA21 or Herceptin treatment alone group. Both VEGF protein expression and MVD values in ChA21 plus Herceptin treatment group were lower than those in the control group, ChA21 or Herceptin treatment alone group.In vitro, the growth and invasion ability of human ovarian cancer cell line SKOV3 were significantly inhibited by treated with ChA21 plus Herceptin for 48 h. The SKOV3 cells treated with ChA21 plus trastuzumab for 12 h secreted less VEGF thanthe cells treated agent alone, and VEGF、pAkt were reduced more effectively bycombined treatment compared with the treatment alone by western bl